Merck reported promising Phase III data for its oral PCSK9 inhibitor enlicitide decanoate, showing significant LDL cholesterol reductions, aiming to capture a spot in a competitive market. Concurrently, Metsera’s long-acting amylin analogue delivered encouraging early clinical results suggesting once-monthly dosing potential and substantial weight loss. The success of both compounds anticipates impactful contributions to cholesterol and obesity treatment landscapes.